Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Telix Pharmaceuticals Limited (TLX.AX)
North Melbourne, VIC, AU
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -2.10% | -13.13% | +30.30% | -14.39% | +16.34% | -49.98% | +11.37% | +189.56% | +1,592.21% | +1,592.21% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 8 | -2 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+59.2% ★ Q4'25: +124.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-123.4% Q4'25: -136.2% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-8.2% Q4'25: -15.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+2.2% ★ Q4'25: +1.6% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+2.3% ★ Q4'25: +3.3% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-2.1% ★ Q4'25: +4.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×12.80× Q4'25: 6.97× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 15 Rev. Ana. 9 EPS Ana. |
Dec 2027 14 Rev. Ana. 8 EPS Ana. |
Dec 2028 12 Rev. Ana. 8 EPS Ana. |
Dec 2029 11 Rev. Ana. 6 EPS Ana. |
Dec 2030 6 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
195.1K
est: 202.7K (-3.7%)
|
3.49M
est: 4.77M (-26.9%)
|
5.21M
est: 21.17M (-75.4%)
|
7.60M
est: 7.67M (-1.0%)
|
160.10M
est: 158.12M (+1.3%)
|
502.55M
est: 645.68M (-22.2%)
|
783.21M
est: 784.11M (-0.1%)
|
1.25B
est: 1.20B (+3.5%)
|
1.35B
1.32B – 1.38B
+12.1% YoY
|
1.58B
1.43B – 1.77B
+17.2% YoY
|
1.89B
1.76B – 2.02B
+19.0% YoY
|
1.91B
1.79B – 2.05B
+1.2% YoY
|
2.30B
2.16B – 2.47B
+20.8% YoY
|
| EBITDA |
-25.82M
est: -97.9K (-26,263.8%)
|
-24.48M
est: -46.97M (+47.9%)
|
-54.20M
est: -39.15M (-38.4%)
|
-70.07M
est: -152.13M (+53.9%)
|
-92.84M
est: -331.46M (+72.0%)
|
22.97M
est: -176.50M (+113.0%)
|
92.55M
est: -4.54B (+102.0%)
|
61.33M
est: -329.39M (+118.6%)
|
-369.35M
-378.18M – -360.43M
-12.1% YoY
|
-432.99M
-483.08M – -390.67M
-17.2% YoY
|
-515.37M
-553.23M – -482.45M
-19.0% YoY
|
-521.33M
-559.63M – -488.03M
-1.2% YoY
|
-629.78M
-676.04M – -589.55M
-20.8% YoY
|
| EBIT |
-15.68M
est: -100.1K (-15,563.4%)
|
-28.71M
est: -59.11M (+51.4%)
|
-59.08M
est: -33.54M (-76.1%)
|
-75.25M
est: -130.36M (+42.3%)
|
-98.22M
est: -284.03M (+65.4%)
|
16.22M
est: -187.01M (+108.7%)
|
92.55M
est: -3.89B (+102.4%)
|
27.55M
est: -349.00M (+107.9%)
|
-391.34M
-400.70M – -381.89M
-12.1% YoY
|
-458.77M
-511.84M – -413.93M
-17.2% YoY
|
-546.06M
-586.17M – -511.18M
-19.0% YoY
|
-552.37M
-592.94M – -517.09M
-1.2% YoY
|
-667.27M
-716.29M – -624.65M
-20.8% YoY
|
| Net Income |
-13.83M
est: -30.08M (+54.0%)
|
-27.87M
est: -46.70M (+40.3%)
|
-44.89M
est: -32.55M (-37.9%)
|
-80.51M
est: -126.51M (+36.4%)
|
-104.08M
est: -47.51M (-119.1%)
|
5.21M
est: 49.19M (-89.4%)
|
49.92M
est: 10.84M (+360.3%)
|
-11.05M
est: -7.13M (-55.1%)
|
4.76M
-94.12M – 186.32M
+166.8% YoY
|
34.29M
-12.11M – 179.38M
+620.6% YoY
|
90.65M
-62.69M – 277.63M
+164.3% YoY
|
214.31M
196.51M – 234.77M
+136.4% YoY
|
353.78M
324.41M – 387.57M
+65.1% YoY
|
| SGA |
9.08M
est: 317.1K (+2,763.0%)
|
11.59M
est: 7.46M (+55.3%)
|
24.48M
est: 18.46M (+32.6%)
|
17.35M
est: 12.00M (+44.5%)
|
44.66M
est: 156.29M (-71.4%)
|
134.16M
est: 442.02M (-69.6%)
|
232.86M
est: 536.79M (-56.6%)
|
368.94M
est: 824.88M (-55.3%)
|
924.96M
902.62M – 947.07M
+12.1% YoY
|
1.08B
978.36M – 1.21B
+17.2% YoY
|
1.29B
1.21B – 1.39B
+19.0% YoY
|
1.31B
1.22B – 1.40B
+1.2% YoY
|
1.58B
1.48B – 1.69B
+20.8% YoY
|
| EPS |
-0.07
est: -0.09 (+21.5%)
|
-0.12
est: -0.06 (-99.7%)
|
-0.17
est: -0.04 (-289.7%)
|
-0.29
est: -0.18 (-63.8%)
|
-0.33
est: -0.28 (-17.9%)
|
0.02
est: 0.15 (-89.3%)
|
0.15
est: 0.24 (-38.2%)
|
-0.03
est: 0.00 (-1,075.8%)
|
0.06
-0.28 – 0.55
+1,573.1% YoY
|
0.16
-0.04 – 0.53
+189.0% YoY
|
0.45
-0.19 – 0.82
+176.9% YoY
|
0.63
0.58 – 0.69
+41.4% YoY
|
1.05
0.96 – 1.15
+65.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - S&P/ASX MidCap ETF MVE.AX | 1.47% | 4.83M | 0.45% |
| 2 | BetaShares - Australian Sustainability Leaders ETF FAIR.AX | 0.83% | 6.14M | 0.49% |
| 3 | Vanguard MSCI Australian Small Companies Index ETF VSO.AX | 0.67% | 5.36M | 0.30% |
| 4 | VanEck - MSCI Australian Sustainable Equity ETF GRNV.AX | 0.62% | 1.02M | 0.35% |
| 5 | BetaShares - Australian Ex-20 Portfolio Diversifier ETF EX20.AX | 0.47% | 2.15M | 0.25% |
| 6 | BetaShares - Geared Australian Equities Complex ETF GEAR.AX | 0.38% | 1.66M | 0.78% |
| 7 | Franklin FTSE Australia ETF FLAU | 0.19% | 290.7K | 0.09% |
| 8 | iShares Core S&P/ASX 200 ETF IOZ.AX | 0.18% | 11.11M | 0.05% |
| 9 | Xtrackers S&P ASX 200 UCITS ETF 1D XAUS.L | 0.18% | 126.1K | 0.50% |
| 10 | BetaShares - Managed Risk Australian Shares Complex ETF AUST.AX | 0.18% | 33.4K | 0.49% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christian Behrenbruch GAICD | Co-Founder, MD, Group Chief Executive Officer & Executive Director | 966.3K | — |
| Darren Smith FCPA | Group Chief Financial Officer | 888.5K | male |
| Darren Patti | Group Chief Operating Officer | 690.4K | male |
| David N. Cade MBBS | Group Chief Medical Officer | 662.0K | — |
| Andreas Kluge | Chief Medical Advisor | 99.4K | — |
| Craig Ulrick | Chief Information Officer | — | male |
| Christian Krautkramer | Group General Counsel | — | male |
| Kyahn Williamson | Senior Vice President of Corporate Communications & Investor Relations | — | female |
| Lena Moran-Adams | Group General Counsel | — | female |
| Meredith Crowe | Senior Vice President of Global People & Culture | — | female |
| Paul Schaffer | SVP of Research & Development | — | — |
| Thomas Fromm | Vice President of Sales | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TLX.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
